The present EPO trial includes, for the first time, first-degree relatives with cognitive impairment (sub-study 1), which will clarify whether EPO has the potential to improve cognitive and functional outcome in genetically predisposed individuals, who are at increased risk of stress and illness onset [86]. The gene discussed is EPO; the disease is Cognitive impairment.